KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Deferred Taxes (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Deferred Taxes for 8 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 87.06% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 63.92% increase, with the full-year FY2025 number at -$3.2 million, up 63.92% from a year prior.
  • Deferred Taxes was -$1.1 million for Q4 2025 at Xenon Pharmaceuticals, down from -$701000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $403000.0 in Q1 2024 to a low of -$8.6 million in Q4 2024.
  • A 5-year average of -$617000.0 and a median of -$185000.0 in 2023 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: soared 2766.67% in 2022, then crashed 4206.0% in 2024.
  • Xenon Pharmaceuticals' Deferred Taxes stood at $346000.0 in 2021, then tumbled by 98.55% to $5000.0 in 2022, then tumbled by 4100.0% to -$200000.0 in 2023, then plummeted by 4206.0% to -$8.6 million in 2024, then skyrocketed by 87.06% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Deferred Taxes are -$1.1 million (Q4 2025), -$701000.0 (Q3 2025), and -$170000.0 (Q2 2025).